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 Targeting angiogenic pathways in colorectal cancer: complexities, challenges 
and future direction 
Khurum Khan, David Cunningham, Ian Chau 
Abstract: 
Colorectal cancer (CRC) is one of the commonest cancers in the world. During the last 
decade, the development of targeted therapies has given cancer treatment a novel 
direction in management of metastatic CRC (mCRC) and has enriched the therapeutic 
armamentarium in the management of this disease. In mCRC, targeting angiogenesis 
via the vascular endothelial growth factor (VEGF) pathway has been of particular 
interest based on the favourable survival benefit demonstrated by bevacizumab in 
clinical trials. More recently, large phase III studies have shown clinical efficacy for the 
new anti-angiogenic agents aflibercept and regorafenib. However, the results of pre-
clinical and clinical studies of other anti-angiogenic agents have been disappointing.  
Furthermore, the benefits from angiogenic inhibitors (AIs) in an unselected patient 
population are modest. Research into predictive biomarkers is therefore essential, but 
has, to date, been unsuccessful.  Nevertheless, aflibercept and regorafenib have been 
shown to benefit both bevacizumab naive and refractory patients, suggesting that 
acquired resistance to AIs can be potentially reversed. This review describes the most 
recent advances in development of AIs in mCRC with particular focus on aflibercept 
and regorafenib, the existing challenges for the evaluation of these agents in clinical 
practice and potential strategies in designing clinical trials that could lead to the 
discovery of clinically meaningful biomarkers. 
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1. Introduction: 
Colorectal cancer (CRC) is one of the fourth commonest cancers in the world and is 
associated with a high morbidity and mortality. In United States, over 1.4 million cases 
of CRC were diagnosed in 2013 and the projected mortality in 2013 was estimated to 
be more than 50,000[1]. CRC accounted for 9% and 8% of all cancer-mortality in males 
and females respectively in 2013[2]. Similarly, in Europe, CRC is the second 
commonest cancer and the second commonest cause of cancer-related mortality in 
both genders [3]. Despite recent improvements in screening and better insights into 
molecular biology of CRC, the 5–year survival rates for patients diagnosed with 
metastatic colorectal cancer (mCRC) remain poor[4]. These data reflect that CRC is a 
significant global health problem and that it requires further attention in terms of 
improving the screening procedures, gaining more insight into better selection of 
patients for existing therapies and the development of new therapies. 
For patients with unresectable mCRC, the treatment goal in majority of the patients 
remains achieving disease control, prolonging survival, and providing palliation of 
symptoms. A small proportion of patients with liver-only metastatic disease may still 
achieve cure after presenting with colorectal liver metastases (CLM)[5]; however, the 
majority of them relapse with unresectable metastatic disease[6, 7].Chemotherapy 
has been the mainstay of treatment in the management of mCRC; from fluorouracil (5-
FU) therapy to current combination treatment options, we have made some significant 
improvements. The median overall survival (OS) has therefore improved from 12 
months with 5-FU monotherapy to 30-33 months with current regimens and the 
estimated median OS has improved from 12 months to 30-33 months with the modern 
regimens [8-13].This improvement in survival outcomes can be partly attributed to the 
incorporation of anti-angiogenic agents into the current therapeutic armamentarium. 
Bevacizumab was one of the first targeted agents to have received regulatory approval 
for use in mCRC [14]; following that the other angiogenesis-inhibitors (AIs) aflibercept 
and regorafenib have received regulatory approvals for use in the second and third 
line mCRC setting respectively [15, 16]. 
In this review, we will discuss the role of angiogenesis in mCRC, the impact of AIs in 
this disease, challenges in selection of patients for AIs and future trial designs that can 
potentially help us overcome these challenges. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. The role of angiogenesis in mCRC: 
Angiogenesis is a complex and tightly regulated physiological process comprising of 
sprouting, splitting, and remodelling of existing vessels. It is regulated by a balance 
between various pro-angiogenic factors (e.g. growth factors, chemokines, enzymes, 
adhesion molecules, and endothelial specific factors) and anti-angiogenic factors (e.g. 
angiostatin, endostatin, thrombospondin, canastatin, and pigment epithelium-derived 
factor) [17, 18]. An imbalance between the pro-angiogenic and anti-angiogenic factors 
has been well-recognised as one of the hallmarks of cancer[19]. Under normal 
physiological conditions, angiogenesis occurs during wound repair, tissue remodelling 
or inflammatory processes; however, this process is deregulated and chaotic in 
neoplasms, which results in leaky, tortuous and inefficient vessels [20, 21] that have 
structural and functional abnormalities. 
One of the most recognised proangiogenic pathways which have potential therapeutic 
implications is the vascular endothelial growth factor (VEGF)/ vascular growth factor 
receptor (VEGFR) signalling pathway. Figure 1 shows the complexity and cross talks 
associated with this pathway. It comprises of a family of homodimeric glycoprotein 
ligands including: VEGF-A, -B, -C, -D, -E and placental growth factor (PIGF) [22, 23]. 
VEGF-A (also commonly referred to as VEGF) which is located on chromosome 6, is 
the most widely known gene in this pathway which undergoes alternative splicing to 
yield mature isoforms of 121, 145, 165, 183, 189 and 206 amino acids[24-26]; of those 
121, 145 and 165 have been shown to be related to angiogenesis in many in vivo 
experiments[27]. Many growth factors and cytokines have been implicated in 
regulation of VEGF pathway; however, the main factor that regulates its expression is 
hypoxia[28]. As a consequence of hypoxic conditions, which most tumours acquire as 
their growth outstrips the blood supply, transcription factor hypoxia-inducible factor-1 
(HIF-1) and HIF-2 are activated, which leads to increased expression of VEGF[29]. 
Additionally, hypoxia also causes up-regulation of VEGF by increasing the stability of 
mRNA51 and by hypoxic translation of the VEGF mRNA [30, 31]. VEGF activation 
then leads to cascade of downstream signals, mainly through VEGFR-2, which is 
normally expressed by endothelial cells [32]. VEGF-B and placental growth factor 
(PIGF) bind to VEGFR-1, whereas VEGF-C and –D bind to VEGFR-2 and -3 receptors 
respectively [32]. The activation of VEGFR-1 by PIGF has been shown to be 
associated with recruitment of monocytes, which may be a means for tumour escape 
from angiogenic signals [33]. In CRC, VEGFR-1 activation also plays a leading role in 
cell survival, tumour progression and development of metastases [34]. VEGF-C and –
D play an important role in lymphangiogenesis and in development of metastases in 
many cancers including CRC by activation of VEGFR-3[35, 36].  
The VEGF pathway is not the only pathway known to be associated with angiogenesis. 
More recently, the human angiopoietin family proteins, Ang-1 and Ang-2 have 
emerged as other important regulators of angiogenesis[37]. Ang-1 and Ang-2 are 
primarily over-expressed in perivascular cells and weibel-palade bodies of endothelial 
cells respectively [38, 39]. Ang-1 stimulates auto-phosphorylation of tyrosine kinase 
receptor (Tie-2), which is expressed by endothelial cells. This leads to activation of 
intracellular signalling pathways, which promote survival, and maintenance of 
endothelial cells under normal physiological conditions [40]. In contrast, Ang-2 is an 
inhibitory ligand for the Tie-2 receptor that disrupts the integrity of normal vasculature 
by competing with Ang-1, thus counteracting vascular normalisation [41-43]. Ang-2 
can be over-expressed in multiple tumour types, including CRC; high Ang-2 levels 
have also been shown to promote metastatic growth and poorer survival outcomes in 
CRC [44-46]. Moreover, higher expression of Ang-2 expression has been associated 
with lymph node metastasis, venous invasion and high microvascular density in CRC 
[47]. Ang-2 ligand secretion is also known to be VEGF-dependent and can be down 
regulated in response and efficacy to anti-VEGF therapy [48, 49]. Blockade of the Ang-
2/Tie-2 axis has however proved to be difficult in comparison to the VEGF pathway 
due to agonistic and antagonistic properties of Ang-1 and Ang-2 ligands respectively. 
However, potential treatment options blocking this pathway are being evaluated in 
clinical trials (NCT02141295). 
Fibroblast growth factor (FGF)/FGF receptor (FGFR) signalling comprises of multiple 
cellular processes that can result in a cascade of downstream signals leading to cell 
growth, survival and angiogenesis. The FGF family includes 22 ligands (FGF-1 to -22) 
and 5 receptors (FGFR-1 to -5) [50, 51]. FGF and VEGF pathways can cross talk with 
each other, therefore promoting angiogenesis; indeed FGF-2 is know to induce the 
expression of VEGF in vascular endothelial cells and it has been shown that blockade 
of VEGF can reduce FGF-2 levels, highlighting the cross talk between the two 
pathways[52]. Likewise the platelet derived growth factor (PDGF) pathway contains 
five PDGF dimeric ligands and two receptors (PDGFR α and β) and is integral to 
regulation of angiogenesis. Activation of the PDGF pathway can lead to intracellular 
signalling cascades which overlap with the VEGF signalling system and in turn 
promote vascular integrity, development and stabilisation[53, 54].  
The epidermal growth factor (EGF) pathway is closely related to the VEGF pathway in 
terms of cross talks leading to resistance mechanisms, thereby affecting the efficacy 
of existing treatment options. Previous in vitro studies have demonstrated that 
increased VEGFR-1 expression can be associated with resistance to anti-EGFR 
therapies like cetuximab and gefitinib (a selective inhibitor of the EGFR tyrosine kinase 
domain), the former of which is licensed for use in mCRC [55]. Moreover, HIFs can be 
up regulated under hypoxic conditions, which then can increase VEGF expression and 
a cascade of downstream events [56]. Furthermore, VEGF production by tumour cells 
may be stimulated by activation of EGFR, which may result in increased migration and 
proliferation of endothelial cells, promoting angiogenesis [57, 58]. Based on close 
crosstalk between the two pathways, and some pre-clinical evidence [59-63], it was 
hypothesised that the dual blockade of VEGF and EGF pathways together may yield 
clinical benefit, however, the studies combining anti-VEGF and anti-EGFR antibodies 
didn’t show any improvement in efficacy [64, 65]. Although several explanations, 
including overlapping toxicities, altered tumour vascularity[66] and downstream 
signalling interactions[65] have been proposed to be potential reasons for lack of 
efficacy when combing the blockade of two pathways, no robust evidence explaining 
the scientific rationale for the failure of dual blockade currently exists. 
 
 
 
 
 
 
 
3. AIs in metastatic colorectal cancer in the clinic: 
As noted before, the management of mCRC has evolved over last decade or so, with 
the median OS improving from 12 months with fluorouracil based single agent therapy 
to 30-33 months with new regimens[8, 11, 13, 67]. Regardless of the sequence of the 
available chemotherapy regimens, the outcome may be optimised in patients who are 
able to receive all the available drugs alone or in combination, including 5-FU, 
irinotecan, oxaliplatin, bevacizumab, aflibercept, regorafenib and 
cetuximab/panitumumab (in RAS wild type patients) during the course of their 
treatment. The currently available drugs, which are approved for treatment of mCRC, 
include three AIs, which highlight the importance of targeting angiogenesis in mCRC. 
In this section we will briefly discuss the available clinical data on approved AIs in 
mCRC. 
3.1. Bevacizumab in mCRC: 
Bevacizumab is a humanised monoclonal antibody, which binds to VEGF-A (Figure 
1), thereby inhibiting its interaction with VEGFR-1 and VEGFR-2 [68]. Bevacizumab 
comprises of human framework regions with 7% murine protein sequence, forming an 
antibody that inhibits all isoforms of human VEGF [69]. Numerous clinical studies have 
demonstrated the efficacy of bevacizumab in mCRC in various combinations, 
sequencing and duration [70]. In the landmark clinical trial comparing a bolus 
Irinotecan, 5-FU and Leucovorin (IFL) regimen with or without bevacizumab, a 
significant progression-free survival (PFS) (10.6 vs. 6.2 months, Hazard ratio [HR] 
=0.54, P<0.001), OS (20.3 vs. 15.6 months; HR =0.66, P<0.001) and objective 
response rate (ORR) (44.8% vs. 34.8%, P=0.004) advantage was observed in favour 
of the bevacizumab arm [71]. This led to US Food and Drug Administration (FDA) 
approval for this drug in mCRC. Subsequently the superiority of infusional versus bolus 
5-fluorouracil (5-FU)-based regimens in combination with bevacizumab was 
established in the 430 patients in the BICC-C study. In this study patients were 
randomised to IFL, FOLFIRI (5-FU with irinotecan), or CAPIRI (capecitabine with 
irinotecan). The trial was later amended to include addition of bevacizumab to the 
treatment arms, which demonstrated an OS advantage in favour of the FOLFIRI plus 
bevacizumab arm, compared with IFL (28.0 vs. 19.2 months)(Table 1)[72]. Other 
studies combining bevacizumab with oxaliplatin have shown conflicting data. In the 
phase III NO16966 trial, a 2x2 factorial design was utilised to evaluate addition of 
bevacizumab or placebo to XELOX (capecitabine and oxaliplatin) or FOLFOX4 (5-FU, 
leucovorin and oxaliplatin). This study demonstrated a minor improvement in PFS (9.4 
vs. 8 months) in favour of bevacizumab containing regimens; however, no significant 
improvement in OS was observed (21.3 vs. 19.9 months, P=0.77) [14]. However, in 
this study a large number of patients were not treated until progression and early 
withdrawal was noted in high proportion of patients and- the results of the study should 
therefore be interpreted with caution. In the TREE study, modified FOLFOX6 with 
bolus 5-FU or CAPOX (capecitabine and oxaliplatin) were compared to addition of 
bevacizumab with or without the two chemotherapy regimens. A median OS of 23.7 
months for the groups receiving bevacizumab was observed compared to 18.2 months 
for the non-bevacizumab groups[73]. It is however noteworthy that the addition of 
bevacizumab was not conducted in randomised fashion; therefore the results of this 
study also need to be interpreted with caution.  
Based on the favourable results obtained from some of the above studies, 
bevacizumab has been often used as first-line treatment in mCRC; however, the 
choice of first-line therapy in RAS wild type tumours remains controversial and should 
be determined based on clinical features and preference of the patients [74]. In view 
of relatively common use of bevacizumab in first line setting, one of the important 
questions that arose is in clinical practice is the use of bevacizumab beyond 
progression. The Bevacizumab Regimens: Investigation of the Treatment Effects and 
Safety (BRiTE) study (600/1953 patients treated beyond progression) was an 
observational study that demonstrated that continuation of bevacizumab beyond 
progression was a single independent factor associated with better OS [75]. The 
concept of maintenance bevacizumab has also been explored in other clinical studies. 
(Table 1)[76, 77]. The CAIRO-3 study investigated the efficacy of maintenance 
capecitabine with bevacizumab versus observation in patients with stable disease or 
response after the induction treatment of CAPOX and Bevacizumab (CAPOX-B). At 
the time of initial progression (PFS1), patients were treated with CAPOX-B until 
second progression in both arms (this time point was referred to as PFS2). PFS2 was 
chosen as the primary endpoint of the study. While the final results of the study are 
yet to be published, this study met the primary endpoint with PFS2 of 11.7 vs. 8.5 
months in favour of CAPOX-B arm[76]. CAIRO-3 was a well-conducted study, which 
took into account the common bias of improving PFS in the maintenance studies as 
PFS2 was chosen as the primary endpoint. Based on the results of this study, patients 
with good response to bevacizumab may be considered for treatment until 
progression; however, clinical factors like extent to response to the treatment, patient 
preference and impact of treatment on quality of life should be carefully considered. 
3.2. Aflibercept in mCRC: 
Aflibercept is a recombinant VEGFR-antibody protein that is generated by fusion of 
the second immunoglobulin (Ig) domain of VEGFR-1 and the third Ig domain of 
VEGFR-2 to the Fc domain of human IgG1 [78]. Aflibercept traps the different isoforms 
of VEGF-A with 1000-fold higher intensity compared to bevacizumab, in addition to 
binding to PIGF and VEGF-B [79]. Aflibercept has been found to be active with a broad 
pharmacological index in number of pre-clinical solid tumour and mouse model studies 
[80-82]. Animal studies showed that aflibercept-VEGF complexes have no platelet-
activating potential, suggesting that pro-thrombotic events were less likely to be 
associated with aflibercept. Phase I studies showed effective pharmacokinetic (PK) 
and pharmacodynamic (PD) effects indicative of effective VEGF blockade and a dose 
of 4mg/kg every 2 weeks was identified as the maximum tolerated dose (MTD) [83]. 
Based on the strong pre-clinical data, demonstration of effective VEGF blockade in 
early phase studies and the success of bevacizumab in mCRC; aflibercept was 
evaluated in mCRC. The phase II AFFIRM study recruited 236 patients with treatment 
naive mCRC to FOLFOX6 with or without aflibercept; however, this study failed to 
demonstrate any survival advantage in favour of aflibercept arm[84]. In the EFC10262-
VELOUR trial, the addition of aflibercept to the standard FOLFIRI regimen was 
evaluated in 1226 patients with mCRC after failure of an oxaliplatin-based 
chemotherapy [15].The addition of aflibercept to FOLFIRI significantly improved OS 
relative to placebo plus FOLFIRI (hazard ratio [HR], 0.817; 95.34% CI, 0.713 to 0.937; 
P = .0032) with median OS of 13.50 versus 12.06 months, respectively. Aflibercept 
also significantly improved PFS; HR, 0.758; 95% CI, 0.661 to 0.869; P < .0001), with 
median PFS times of 6.90 versus 4.67 months, respectively. The effects on OS and 
PFS showed a consistent trend across all pre-specified subgroups, including 
bevacizumab pre-treated patients. ORR was 19.8% (95% CI, 16.4% to 23.2%) with 
aflibercept plus FOLFIRI compared with 11.1% (95% CI, 8.5% to 13.8%) with placebo 
plus FOLFIRI (P = .0001). These data led to the approval of aflibercept in combination 
with FOLFIRI in patients who have refractory disease to first-line oxaliplatin based 
treatment. 
3.3. Regorafenib in mCRC:  
Regorafenib (BAY73-4506) is an oral multi-kinase inhibitor (MKI), which has anti-
angiogenic (VEGFR-1, -2, -3, PDGF, Tie-2, and FGFR) [85], anti-oncogenesis (KIT, 
RET, RAF1, BRAF) and anti-stromal (PDGF and FGFR) [86] properties. Pre-clinical 
studies confirmed a broad spectrum of anti-tumour activities [86, 87]. In a phase 1b 
study, 38 patients with heavily pre-treated (median 4 lines of prior treatment) mCRC 
were enrolled (dose escalation n=15, dose expansion n=23). Of the 27 evaluable 
patients, 1 (4%), 19 (70%) and 7 (26%) had a partial response (PR), stable disease 
(SD) and progressive disease (PD) respectively. The median PFS was 107 days and 
there was no statistically significant difference found in the PFS of KRAS mutant or 
wild type patients [88]. Following this, regorafenib was evaluated in a large phase III 
study. This study included 760 patients, nearly all of who were refractory to oxaliplatin, 
irinotecan and fluoropyrimidines, who had progressed within three months of the last 
therapy. Patients were randomised in 2:1 fashion to regorafenib (n=500) or placebo 
(n=253) respectively. This study demonstrated a statistically significant difference in 
OS and PFS in favour of regorafenib; with a median OS of 6.4 months versus 5.0 
months (HR =0.77, 95% confidence interval [CI] =0.64-0.94, P=0.0052); and median 
PFS of 1.9 versus 1.7 months (HR=0.49M 95% CI=0.64-0.94, P=<0.000001)[16].  
These data led to the FDA and EMA approvals of this product in the refractory mCRC 
setting. However, regorafenib is currently not commonly used due to the modest 
benefit in OS and the current lack of a validated biomarker. There are a number of 
clinical trials being designed or currently recruiting which are investigating the efficacy 
of regorafenib in other indications for mCRC. 
3.4. Ramucirumab in mCRC:  
Ramucirumab (IMC-1121B) is a fully humanised monoclonal antibody that potentially 
blocks the binding of the VEGF ligand to VEGFR-2 receptors by binding to the 
extracellular domain of VEGFR-2 receptors with high affinity [89, 90].  PD data from 
pre-clinical studies confirmed that ramucirumab effects the VEGF/CEGFR-2 
interaction, VEGF-stimulated VEGFR-2 activation, proliferation of human endothelial 
cells and VEGF-induced phosphorylation of VEGFR-2 in both human umbilical vein 
endothelial cells and porcine aortic endothelial cells over-expressing VEGFR-2 [91]. 
Ramucirumab has demonstrated strong anti-tumour activity as single agent and in 
combination with other therapies in a range of malignancies in animal models [89]. It 
has also been evaluated in mCRC; although the results from a large phase III study in 
second-line mCRC are currently awaited, an initial press release from the drug 
company suggests that the drug may have shown efficacy in this setting. Considering 
the success of AIs (aflibercept and regorafenib) after failing on bevacizumab coupled 
with the activity demonstrated by ramucirumab in gastric cancer in treatment-refractory 
patients [92], it will not be surprising if the drug shows efficacy in refractory mCRC. 
This will further open the window of opportunity for clinical trials in various lines of 
mCRC and will potentially add treatment options that are available for this disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Current research challenges:  
In recent years, there has been more emphasis on the development of targeted 
therapies that are selected based on the understanding of patient’s tumour biology 
and molecular characteristics. The search for biomarkers that can predict response or 
resistance to specific therapeutic interventions has therefore become increasingly 
important in order to ensure that the right treatment can be selected for the right 
patients. The clinical observation that a significant proportion of patients who receive 
AIs may have improvement in PFS, which may not translate into an OS advantage, 
suggests that there are acquired mechanisms of resistance to AIs, which are 
incompletely understood. Furthermore, unlike cytotoxic chemotherapy, AIs may cause 
cytostatic effects, therefore the reliance upon Response Evaluation Criteria In Solid 
Tumours (RECIST) criteria may not provide useful insights into real clinical benefit 
from these agents. More precise information may therefore be gained from the use of 
biomarkers in determining the optimal dose and duration of AIs [93]. Here we discuss 
the issues surrounding the success of antiangiogenic therapies in mCRC and need for 
clinical trials prospectively validating this approach so that rigorously validated 
biomarkers are available for clinical use in order to optimise benefits from anti-
angiogenic therapies. 
 
4.1. Resistance to AIs: 
Since Judith Folkman’s initial hypothesis that angiogenesis could be explored as a 
therapeutic target [94], significant progress has been made in the last four decades 
with the development of a number of AIs. However, despite the encouraging pre-
clinical results, AIs in most solid malignancies have failed to demonstrate a sustained 
anti-tumour activity and the magnitude of benefit across most tumour types has been 
rather modest [95]. As noted before, a number of clinical trials in mCRC and other 
cancers demonstrated significant improvements in PFS, which didn’t translate into a 
improvements in OS; suggesting that both intrinsic and acquired mechanisms of 
resistance to AIs exist [96]. One of the important clinical observations made through 
several clinical trials is that AIs may show efficacy in three different ways: a) tumours 
show vascular response and associated significant shrinkage in the size of the tumour 
(cytotoxic effect) or b) tumours show vascular response but no accompanying tumour 
shrinkage (cytostatic effect) or c) tumours show minimal vascular response and 
stabilisation of the disease [97]. This suggests that tumours perhaps have adaptive 
vascular and extra-vascular mechanism to overcome treatment with AIs. It is therefore 
of pivotal importance to develop a good understanding about these response and 
resistance mechanisms so that strategies can be developed to effectively overcome 
such challenges. Here we discuss important proposed mechanisms of resistance to 
anti-angiogenic therapies. 
4.1.1. Blood vessels heterogeneity and alternative tumour vascularisation: 
The tumour vessels are heterogeneous which may influence the response or 
resistance to AIs. Pre-clinical studies have demonstrated that anti-VEGF therapy 
suppresses the newly formed vessels more effectively compared to mature vessels 
[98, 99]. This may be due to dependence of nascent vessels on VEGF and on 
maturation, the sensitivity to anti-VEGF agents may be lost [97]. As pericyte 
recruitment into the vessels mediated by PDGF is one of the important aspects of 
vessel maturation, the clinical effects seen by use of MKIs (e.g., sorafenib, sunitinib 
and regorafenib) may be due to targeting of pericytes [100, 101]. Moreover, despite 
the common belief that the VEGF pathway is primarily responsible for sprouting 
angiogenesis, it is increasingly recognised that tumour vascularisation may be 
dependent on various diverse mechanisms [102, 103]. These alternative mechanisms 
of tumour vascularisation are well described in the literature in various human 
malignancies, and in other reviews [97] in more detail; we will briefly describe “vessel 
co-option” model here which may be more closely related to CLM [104]. Vessel co-
option occurs when tumours invade the surrounding tissue and recruit existing blood 
vessels. Vessel co-option has been a well described phenomenon in various 
malignancies including glioblastoma [105], melanoma [106], adenocarcinoma of the 
lung[107] and liver metastases from breast and colorectal cancers [104, 108]. The 
clinical implication of this could be exploiting the role of histological growth patterns 
and response to chemotherapy in patients undergoing chemotherapy combinations 
with AIs. It is of particular interest in patients with CLM, as up to 40% of such patients 
may undergo tumour resection after having initial chemotherapy; this may provide an 
opportunity for high quality tissue collection and forming an association with 
radiological responses in a prospective fashion.  
In addition to heterogeneity of tumour vasculature, alternative pro-angiogenic 
pathways may stimulate angiogenesis by activating blood vessel formation when the 
VEGF pathway is blocked. Numerous pre-clinical studies have identified alternative 
candidates, which may become activated on blockade of VEGF pathways; these 
include angiopoietins, FGF1 and FGF2[109], PDGF-C[110], PIGF[111], hepatocyte 
growth factor (HGF) [112], interleukin (IL)-8 [113], delta-like ligand 4 (DLL-4)-Notch 
pathway [114], and EGF [96]. Although a strong body of pre-clinical evidence supports 
the notion that alternative angiogenic pathways may be important adaptive mechanism 
of resistance when treating patients with AIs, the clinical validation of such findings are 
currently lacking. Rational clinical designs facilitating tissue collection at various time 
points may be extremely helpful in validating such findings (as discussed below). 
4.1.2. Stromal infiltration: 
Stroma comprises of a heterogeneous cell population including fibroblasts, immune 
cells (lymphocytes, monocytes and granulocytes), myeloid cells (CD11b+ Gr+) and 
vessel forming cells (endothelial cells and pericytes), which are required by solid 
tumours for their growth and proliferation [115]. Evidence to the fact that stromal cells 
may play an important role in tumour progression [116, 117], and that they can lead to 
resistance to various therapies including AIs [118, 119], is well recognised. Several 
pre-clinical studies have demonstrated that invasion of tumours by various stromal 
cells can mediate resistance to AIs [120, 121]. Although the exact mechanism of 
resistance mediated by stromal cells to AIs is incompletely understood, several 
proposed mechanisms include release of pro-angiogenic factors and averting immune 
surveillance [122]. Indeed immature myeloid cells and endothelial progenitor cells 
(EPCs) may induce resistance by directly invading the tumour vasculature [97, 123] or 
through secretion of angiogenic factors like BV-8[124] or PDF-C [110]. Moreover, dual 
blockade of granulocyte colony stimulating factor (G-CSF), which is a key regulator of 
BV-8 expression, and the VEGF pathway has been shown to be associated with 
enhanced anti-tumour activity [125].  Although dual blockade of angiogenesis and 
stromal cells appears promising on review of pre-clinical data, it may be extremely 
challenging to block stromal cells in clinical practice. This is because stromal cells are 
genetically stable compared to cancer cells which carry genetic aberrations; however, 
they are constantly instructed by cancer cells in the tumour micro-environment. It is 
therefore possible that the stromal cells have different molecular and cellular 
characteristics based on the tumour type. Furthermore the intra-tumour heterogeneity 
exhibited by tumour cells within the same patient may make it even more challenging 
to targeting stroma with a “one size fits all” approach.  
4.2. Lack of validated biomarkers 
The search for predictive biomarkers that can determine response to anti-cancer 
therapies is one of the biggest challenges for the application of precision medicine in 
the clinic. Predictive biomarkers have allowed the rational use of targeted oncology 
therapies in patients with some solid cancers like breast cancer, gastrointestinal 
stromal tumours (GIST), non-small cell lung cancer and metastatic melanoma [126]. 
The only validated predictive biomarker in mCRC thus far remains mutation in RAS 
genes, which are a negative predictive marker of response to anti-EGFR therapies. 
The search for biomarkers to anti-angiogenesis therapies has proven to be challenging 
due to complexity of tumour-host interactions and the complexity of the VEGF 
pathway. There are number of potential biomarkers that have been examined in 
various clinical studies, however, none of them have been validated vigorously in 
prospective clinical trials in order for them to be used regularly in the clinic. 
4.2.1. Circulating biomarkers: 
VEGF-A has been investigated as a predictive biomarker in clinical trials of different 
malignancies including mCRC [127]. Although alterations in circulating VEGF levels 
have not been shown to be associated with treatment outcomes with anti-VEGF 
therapy in the clinic, they may serve as important PD biomarkers [93]. A phase I/II 
study of combination of chemotherapy and bevacizumab in rectal cancer patients 
showed that plasma VEGF and PIGF levels were significantly raised in patients 
receiving anti-VEGF therapy, suggesting that these could be utilised as PD markers 
[128].There is evidence from preclinical models that adaptive exposure of 
bevacizumab to CRC cells results in increased invasive capacity and migration after 
one week of exposure; increased expression of VEGFR-1, PIGF and VEGF-B was 
also noted in the cells which were chronically exposed to bevacizumab [129]. Loupakis 
et al. found an association between resistance to bevacizumab and low active VEGF 
concentrations; however, the VEGF levels remained low at the time of progression, 
contrary to PIGF and VEGFR-2 levels which were increased at the time of disease 
progression [130]. The AVAGAST [131] (Avastin in advanced gastric cancer trial) also 
showed that low VEGA levels were associated with improved outcomes, however, 
these findings were not reproduced by similar studies in CRC [132]. Other studies 
showed that VEGFR-2 and VEGFR-3 levels were associated with response to 
bevacizumab in breast cancer and renal cell carcinoma [133, 134]. Validation of these 
findings by further prospective studies is however lacking at this stage, which restricts 
use of these potential biomarkers in the clinic. 
Circulating endothelial progenitor cells (CEPCs) or circulating endothelial cells 
(CECs), which are released from the bone marrow to the blood have also been 
investigated as potential biomarkers to anti-angiogenic therapies [127]. Some trials 
have shown correlation between the lower number of CECs and response to anti-
angiogenic therapy; while others have shown that higher numbers of CECs can be 
associated with progression of disease[135, 136]. Serum carcinoembryonic antigen 
(CEA), a commonly used biomarker in mCRC, has also been shown to potentially 
increase the sensitivity of VEGF in patients treated with bevacizumab [137]. DNA 
excision repair protein (ERCC-1) and thymidylate synthase (TS) genes expression 
have also been shown to be associated with improved OS in patients with mCRC that 
were treated with FOLFOX4 and PTK/ZK (a selective inhibitor of VEGF-mediated Flt-
1 and KDR receptors) in the first and second line settings respectively [138]. Another 
study examining the gene expression profiles of cancer cells and tumour-associated 
macrophages in tumour biopsies before and on day 12 of bevacizumab monotherapy 
in patients with rectal cancer identified up-regulation of stromal cell-derived factor 1 
alpha (SDF1-α) and its receptors CXCR4, and CXCL6. In addition higher SDF-1α 
levels during bevacizumab treatment was associated with higher rates of distant 
metastases at 3 years [139]. These findings suggest that the SDF1/CXCR4 pathway 
could represent a candidate pathway for validation in clinical studies in order to inform 
mechanism of response or resistance to AIs. The expression of other secreted 
proteins linked to angiogenesis and detected in circulation in various studies, includes 
VEGF-B, VEGF-C, VEGF-D, VEGFR2, FGF1, FGF2, PDGF-A, PDGF-C, HGF, Ang1, 
Ang2, interleukins including: IL-6, IL-8, IL-10, IL-12, MCP-1, tumour necrosis factor 
(TNF)-alpha, matrix metallopeptidase (MMP-9), tissue inhibitor of metalloproteinases 
(TIMP-1), soluble vascular cell adhesion molecule (sVCAM-1), soluble intercellular 
adhesion molecule (sICAM1), E-selectin and osteopontin.  
The above discussion summarises the number of potential biomarkers which may 
have a role to play in future management of patients being treated with anti-angiogenic 
therapies in mCRC; however, none of them have been validated in prospective clinical 
trials and so are unavailable in the clinic. Additionally, there are number of challenges 
in quantification of circulating cytokines as biomarkers of response to anti-angiogenic 
therapies; e.g. circulating VEGF may not provide accurate value as improper handling 
of platelets may release VEGF in to the circulation [122]. Moreover, anti-VEGF 
antibodies like bevacizumab or aflibercept may form complexes with circulating VEGF 
that is still measured as total VEGF, providing a false estimate of circulating VEGF in 
the plasma [140]. Despite all these limitations, circulating biomarkers may have an 
important role to play in future management of mCRC. As noted before there are at 
least three anti-angiogenic therapies now approved for management of mCRC. 
Exploration of biomarkers in clinical trials will help improve our knowledge about these 
biomarkers and therefore facilitate incorporation of them into future clinical practice. 
4.2.2. Imaging biomarkers: 
Imaging modalities have been employed to establish tumour response to anti-
angiogenic therapies, as they permit inspection of tumour morphology and blood flow, 
which are important parameters in determining response or resistance to anti-vascular 
therapies. There is some evidence that dynamic contrast enhanced MRI (DCE-MRI) 
can be helpful in evaluating the tumour vascular heterogeneity and anti-angiogenic 
effects [141]. The effects of anti-angiogenic treatment can be detected by using DCE-
MRI as early as 48 hours after initiating treatment [142]. One of the caveats however 
is that the vast majority of mCRC patients present with or develop CLM and in the 
presence of CLM, response to anti-angiogenic treatment may be modified by the 
predominant vascular pattern associated with the CLM [5]. Nevertheless, DCE-MRI 
has been recognised as a new imaging biomarker of anti-angiogenic activity and its 
parameters (Ktrans) have been correlated with microvessel density and in some 
tumours with degree of VEGF expression [143]. Moreover, hypervascular metastases 
were found to be an independent predictor of disease progression in a study of 
metastatic breast cancer patients [144]. It is well established that CLM demonstrate 
variable degrees of hypervascular rim enhancement, which may correspond with a 
peri-tumoural desmoplastic reaction, peritumoural inflammation, and vascular 
proliferation at histopathological examination [145]. It is thus possible that the 
thickness of the enhancing rim and the quantitative MR vascular parameters 
associated with the peri-tumoural rim of tumour metastases may reflect the degree of 
neo-angiogenesis. DEC-MRI therefore can be potentially used as a useful tool to 
assess response to anti-angiogenic therapies in mCRC. Diffusion weighted magnetic 
resonance imaging (DW-MRI) is another imaging modality, which offers useful 
information about the tumour cellularity and its parameter of Apparent Diffusion 
Coefficient (ADC) is known to be an emerging biomarker of anti-tumour response; with 
an increase in ADC associated with tumour necrosis [146]. Anti-angiogenic therapies 
may cause cellular swelling due to reduction in the blood flow to the tumour area, 
leading to  reduction in the ADC; DW-MRI therefore may provide useful information in 
determining response to anti-angiogenic therapies [146, 147]. Finally, positron 
emission tomography (PET) has been utilised as imaging biomarker for AIs in some 
studies; Zr-ranibizumab, a VEGF-labelled compound, showed promising results as an 
imaging biomarker in a xeno-patient study, during and after treatment with 
sunitinib[148].  However, more vigorous data are required before PET can be used as 
a routine imaging biomarker in the clinic [122]. 
Although validation of imaging biomarkers is required, the fact that they are becoming 
increasingly available in many research centres means that imaging biomarkers are 
likely to be available and validated for use in the clinic in the near future. 
4.2.3. Surrogate biomarkers: 
Blockade of VEGF can lead to reduction in nitric oxide (NO) synthesis, which can lead 
to vasoconstriction and development of hypertension [149]. Hypertension (HTN) has 
thus been considered as another biomarker of response to angiogenesis inhibitors. 
Studies of bevacizumab and systemic chemotherapy combinations used in the 
treatment of mCRC and metastatic breast cancer showed that grade 2-4 HTN was 
associated with significantly better survival and response rates in both cancers 
respectively [150, 151]. Moreover, Schneider et al. showed that VEGF-2578AA (a 
single nucleotide polymorphism [SNP]) in patients with grade 3-4 HTN, was associated 
with a better OS and ORR compared to VEGF-2578CA and VEGF-2578CC genotypes 
[151]. Of note, there are other studies examining the relevance of various SNPs in 
patients receiving anti-angiogenic therapies, however a detailed description of them is 
beyond the scope of this review and has been previously discussed extensively in 
other reviews[152].  
As noted above, HTN can only be used as a surrogate biomarker, as a number of 
other patho-physiological factors may contribute to the development of HTN and 
treatment with anti-angiogenic therapies may not always lead to rise in blood pressure. 
Nevertheless, HTN can be a useful clinical indicator of response or resistance to anti-
angiogenic therapies when coupled with tumour markers like CEA and CA19-9 in the 
clinic. 
4.3. Clinical trial designs to facilitate biomarker discovery: 
One of the lessons learnt from number of seminal studies evaluating the role of RAS 
and other mutations as predictive biomarkers of response to anti-EGFR therapy is that 
the retrospective analysis of the banked tissue may have some limitations. These 
include the quality and quantity of the banked tissue, lack of availability of fresh tissue 
limiting some sequencing analyses and the statistical issues like the results not 
reflecting the intention to treat population. It is therefore imperative that prospective 
tissue collection studies with adaptive designs are designed to overcome such 
challenges. Contemporary prospective biomarker studies will benefit from a better 
understanding of tumour heterogeneity, access to novel sampling techniques like 
liquid biopsies and more advanced sequencing technologies.  
One of the issues with biomarker-driven clinical studies is the uncertainty about the 
appropriate statistical models and endpoints. Some of the earliest biomarker-driven 
studies used an enrichment trial design, which means that only the positively screened 
patients for a specific biomarker were included in the randomised cohorts [153]. The 
issue with enrichment designs are however two-fold; a) this design may significantly 
reduce the number of subjects in the study, which are required for biomarker validation 
and b) this design will only be useful when there is compelling evidence to believe that 
the preliminary data are robust enough to preclude other patients participating in the 
studies modelled on such designs. Enrichment trial deigns are therefore not likely to 
be of clinical utility in establishing biomarkers for anti-angiogenic therapies as firstly, 
there are no robust preliminary data for biomarkers for angiogenesis and secondly, 
anti-angiogenic therapies effect the tumour stroma and thus may not have been 
selected merely based on the tumour’s molecular characteristics. Another approach 
might be to use hybrid designs, where a sub-group of patients are randomised to 
targeted therapies based on a biomarker, and another group is randomised to the 
standard of care treatment. Advantages of hybrid designs compared to enrichment 
designs are that  they allow  larger groups of patients to be analysed and potential 
biomarkers can be thus assessed in all randomised patients across both groups[154]. 
However, when considering biomarkers for anti-angiogenic therapies, hybrid designs 
will be faced with similar limitations due to the lack of any compelling evidence to single 
out a biomarker. Adaptive trial designs that evaluate the success of biomarkers based 
on an ongoing basis may well be therefore required to meet challenges associated 
with anti-angiogenic therapies. We have started a number of tissue collection studies 
in our institute which incorporate prospective tissue collection at various time points. 
This will allow us the opportunity to overcome the issues associated with tumour 
heterogeneity. In addition, these hypothesis-generating studies may provide useful 
insights into issues like concordance between tissue and liquid biopsies. Finally, where 
possible, biomarker studies should be performed in monotherapy studies so that 
contamination due to changes in tumour molecular characteristics resulting from other 
therapies can be minimised (Figure 2). 
 
 
 
 
 
 
 
5. Future directions:  
Clinical efficacy demonstrated by AIs in mCRC provides the proof-of-principle that 
attacking angiogenesis is a valid treatment strategy in this disease. It is however clear 
from both pre-clinical and clinical data that some cancer cells start closer to the point 
of commitment to angiogenesis than others, and they are more likely to be sensitive 
to AIs; others demonstrate intrinsic/acquired resistance to these agents. The spiralling 
cost and complexity of developing AIs, and their impact on a proportion of patients 
warrants that the key issues in their development are addressed so that the full 
potential of this treatment strategy can be ensured in the clinic. Some of the important 
considerations are outlined below: 
5.1.1. Understanding the biology of cancers: 
It is now well established that tumours exhibit both intra-tumour and inter-tumour 
heterogeneity which complicates the process of precision medicine and biomarker 
discovery [155]. Most of the information available to date is restricted to the macro-
heterogeneity level; however, much of the uncertainty surrounds the origin of micro-
metastatic disease and clonal evolution of cancer cells at the micro-heterogeneity 
levels. Some studies have demonstrated that in patients with multiple metastases, 
variable response to AIs was observed with some metastatic lesions responding to the 
treatment while others were progressing [156]. This observation suggests that 
understanding the role of cancer evolution is critically important in establishing the 
novel therapeutic approaches for AIs and for other targeted therapies so that clinical 
outcomes can be improved. 
Additionally, as noted earlier, tumours may vascularise by different mechanisms than 
VEGF-driven angiogenesis.  Furthermore, previous clinical studies indicated that 
whilst bevacizumab was effective in metastatic setting, it showed little clinical efficacy 
in the adjuvant clinical trials in mCRC [157, 158].However, post-hoc analysis of one of 
the recent trials showed that patients with mismatch repair deficiency (dMMR) derived 
statistically significant survival benefit from the addition of bevacizumab when 
compared to those with MMR proficient tumours [159]. These observations may 
suggest that a) VEGF-driven angiogenesis is likely to play an important role only in 
established macro-metastatic disease [97] and/or b) AIs may have a role in only a 
proportion of patients with early commitment to angiogenesis, i.e. at the time of 
developing micro-metastatic disease. There are currently a number of clinical trials 
examining the role of AIs in various solid malignancies in the adjuvant setting; however 
it is concerning that they may not demonstrate efficacy unless biomarker driven trials 
with sound scientific rationale are conducted.  
In order to ensure that better results from the ongoing clinical trials are achieved, it is 
imperative that we improve our understanding of tumour heterogeneity and tumour 
vasculature heterogeneity of both primary and metastatic sites. As noted before, one 
such window of opportunity lies in the management of CLM due to the unique 
opportunity of obtaining viable tissue in the patients undergoing resection and the 
interesting biological behaviour of these cancer as they represent both macro and 
micro-metastatic disease[5]; in such patients valuable information can be gained about 
the role of neo-adjuvant chemotherapy and the histological growth patterns of the 
resected liver metastatic disease. Moreover, understanding the various histological 
growth patterns and their respective response to AIs in this setting will help in 
understanding the impact of vascular heterogeneity in these cancers. Finally, the 
scientific information gained from such studies could have broader applications in 
establishing biomarkers of response and resistance to AIs. 
5.1.2. Biomarker-driven trials and collaborations: 
Tumour endothelial cells tend to be genetically stable compared to tumour cells which 
may have mutations, deletions or amplifications; the response of the tumour 
vasculature to AIs therefore can be a host-mediated response that can be influenced 
by the genetic variability of the host[132]. Several studies have examined the 
predictive role of SNPs in candidate genes in trials where bevacizumab or other AIs 
were used [151, 160-164]; however, in almost all of these studies only limited numbers 
of SNPs were used based on candidate gene approaches. This has resulted in 
heterogeneous data which has not been validated and replicated and therefore is not 
commonly used in clinical practice. This brief discussion reflects upon the urgent and 
un-met need of developing biomarkers that can be validated in larger prospective 
clinical trials. Moreover, there is a growing need to examine the novel biomarkers in 
both plasma and solid tissue; and candidate biomarkers should be examined against 
the advanced imaging techniques like DCE-MRI or DW-MRI so that a homogenous 
set of biomarkers with broader clinical implications become available. Besides the 
scientific challenges in establishing such studies, other pertinent issues include the 
inclusion of biomarker studies in current health-care models and the financial 
implications which need to be met in order to set up these studies. Global 
collaborations are therefore required between clinicians, academics and funding 
bodies to build such research ecosystems. One such example includes the initiative 
taken by European Innovative Medicines Initiative (IMI) - the IMI consortium includes 
21 European sites who are working together to obtain ethically approved metastatic 
tissue from paired biopsies from patients with mCRC [126]. The ultimate aim of this 
consortium will be to apply major sequencing techniques on the collected tissue in 
order to obtain valuable information on the genomics, proteomics, transcriptomics and 
epigenetics of these paired samples. Finally, by incorporating statistical and system 
biology approaches, and by forming collaborations between industry and 
clinicians/scientists, we will get closer to our aim of achieving precision medicine for 
our patients with mCRC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Conclusion:  
In conclusion the pivotal role of angiogenesis in cancer evolution and progression is 
well-established. Moreover, in mCRC AIs have demonstrated efficacy in various 
clinical settings, supporting the hypothesis that angiogenesis is central to the survival 
of cancer cells. Further work on determining the exact structure of tumour vasculature, 
and interaction with alternative signalling pathways will provide a sound platform for 
developing bio-marker driven studies, which will allow us to overcome the challenges 
of tumour heterogeneity, and acquired tumour resistance. Validated biomarkers are 
essential to identify patients most likely to benefit from treatment with AIs and therefore 
optimise their clinical utility. Finally, close collaborations between scientists, clinicians 
and industry will help guide clinical decisions for patients with mCRC, according to the 
desired principles of precision medicine. 
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Table 1: Landmark clinical trials of angiogenesis inhibitors in mCRC: 
First author No. 
of 
pts. 
Line of 
therapy 
Median PFS 
(in months) 
Median 
OS(in 
months) 
Median 
ORR (%) 
Chemotherapy 
combination 
Comments 
                                                            Bevacizumab in mCRC 
Hurwitz[71]  813 First  10.6 vs. 6.2 
P<0.001) 
20.3 vs. 
15.6 
P<0.001) 
44.8% 
vs. 
34.8%, 
P=0.004 
IFL+Bev 
vs. IFL 
Lack of 
randomised 
data for 
FOLFIRI; IFL 
not a standard 
regimen these 
days 
Fuchs [72, 
165] 
117 First  28.0 vs. 
19.2 
(P=0.037) 
 FOLFIRI+Bev 
vs. mIFL+Bev 
 
Stathopoulo
s[166]  
222 First   25.0 vs. 
22.0 
(P=0.139
1) 
36.8% 
vs. 
35.2% 
FOLFIRI+Bev 
vs. FOLFIRI 
 
Hochster[73] 223 First FOLFOX6= 
9.9 vs. 8.7 
bFOL=  
8.3 vs. 6.9 
CAPOX= 
10.3 vs. 5.9 
FOLFOX
6= 26.1 
vs.19.2 
bFOL=  
20.4 
vs.17.9 
CAPOX= 
24.6 
vs.17.2 
FOLFO
X6= 
52% vs. 
41% 
bFOL=  
39% vs. 
20% 
CAPOX
= 
46% vs. 
27% 
FOLFOX6, 
bFOL, CAPOX 
with or without 
Bev 
 
Saltz[14] 140
1 
First  9.4 vs. 8.0 
(P=0.023) 
21.3 vs. 
19.9 
(P=0.077) 
38% vs. 
38% 
FOLFOX or 
XELOX with out 
without Bev 
Drug dosage 
lower than 
usual 
Bennouna, J 
[77, 167] 
820 First/Secon
d, beyond 
progression 
5.7 vs. 4.1 
(P=<0.001) 
11.2 vs. 
9.8 
(P=<0.01) 
5% vs. 
3% 
Irinotecan or 
oxaliplatin 
based 
chemotherapy 
with or without 
Bev  
Results 
independent of 
the KRAS 
status 
Giantonio[16
8] 
829 Second or 
beyond 
7.3 vs. 4.7(P 
< .0001) 
12.9 vs. 
10.8 
(P=0.001
1) 
22.7% 
vs. 8.6% 
(P=< 
.0001) 
FOLFOX4 with 
or without Bev 
or Bev alone 
 
                                                             Aflibercept in mCRC 
Pericay[84] 236 First  8.4 vs. 8.7  49.1% 
vs. 
45.9% 
FOLFOX6 with 
or without 
aflibercept 
Paper not 
published so 
far but 
aflibercept 
only licensed 
for use with 
FOLFIRI 
Van 
Cutsem[15] 
614 Second  6.9 vs. 4.6 
(P=0.0001) 
13.5 vs. 
12.06 
(P=0.003
2) 
19.8% 
vs. 
11.1% 
FOLFIRI with or 
without 
aflibercept 
Led to 
licensing of 
aflibercept in 
second line 
mCRC 
                                                               
 
                                                              Regorafenib in mCRC 
Grothey [16] 760 Convention
al treatment 
refractory 
1.9 vs. 1.7 
(P=<0.00000
1) 
6.4 vs. 
5.0 
(P=0.005
2) 
 Regorafenib vs. 
placebo 
Led to 
licensing of 
regorafenib in 
treatment 
refractory 
mCRC 
 
No=number, pts= Patients, Bev=Bevacizumab, OS=Overall survival, ORR=Overall 
response rate, mCRC=Metastatic colorectal cancer, IFL=Irinotecan, 5-FU and 
leucovorin, FOLFIRI=5-FU and Irinotecan, FOLFOX6= 5-FU and oxaliplatin, CAPOX 
or XELOX=Capecitabine and oxaliplatin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Ongoing clinical trials with Angiogenesis inhibitors with a biomarker 
component 
Drug Trial Phase Treatment arms  Line of 
therapy 
Primary 
endpoint 
Bevacizumab NCT01640405 
(VISNU-1) 
III  FOLFOX + Bev Versus  FOLFOXIRI + Bev as 
First Line Treatment of Patients With mCRC 
Not Previously Treated and With Three or 
More Circulating Tumoral Cells (CTCs) 
First PFS 
OS 
CTCs 
 
 
NCT01937715 
 
I/II A Study Of PF-05212384 Plus FOLFIRI 
Versus Bev Plus FOLFIRI In mCRC 
 DLT 
PFS 
PI3K 
phosphorylation 
 NCT01640444 
(VISNU-2) 
II Influence of BRAF and PIK3K Status on the 
Efficacy of FOLFIRI Plus Bev or Cetuximab in 
Patients With RAS Wild-type mCRC and < 3 
CTCs 
First OS 
CTCs 
Aflibercept NCT02079220 II A Phase II Study of Ziv-aflibercept in 
Combination with XELOX Chemotherapy in the 
Front-Line Treatment of Patients With mCRC 
First  PFS 
 NCT02045030 II Study to Identify Biomarkers of Clinical 
Response to Aflibercept in Patients With 
mCRC 
 Biomarker 
 NCT01661972 
(X-TRAP) 
I/II Phase I/II Study of Capecitabine Plus 
Aflibercept to Treat mCRC 
Treatment 
refractory 
or unfit 
R2PD 
 NCT01661270 
(AFLAME) 
III A Study of Aflibercept Versus Placebo With 
FOLFIRI in Patients With mCRC Previously 
Treated With an Oxaliplatin Chemotherapy 
Second PFS 
 NCT02173990 
(PULSAR) 
II mCRC Treated With First-line Aflibercept-
based Treatment 
First PFS 
DCE-US 
evaluation 
(biomarker) 
 NCT02129257 
(AMALTHEA) 
II Clinical Trial of Combination Chemotherapy 
With Aflibercept in Patients With Advanced 
Colorectal Cancer 
First  PFS at 1 year 
Biomarkers  
 NCT01652196 II Aflibercept and FOLFOX6 Treatment for 
Previously Untreated Stage IV Colorectal 
Cancer 
First PFS 
Regorafenib NCT01298570 II Regorafenib+FOLFIRI Versus 
Placebo+FOLFIRI as 2nd Line treatment in 
mCRC 
Second PFS 
 
 NCT01949194 II Study to Determine the Efficacy of Regorafenib 
in mCRC Patients and to Discover Biomarkers 
Second   Biomarkers 
 NCT01875380 
(REFRAME) 
II Regorafenib in Frail and/or Unfit for 
Chemotherapy Patients With mCRC 
First PFS at 6 
months 
 
 NCT02175654 
(PREVIUM) 
II Regorafenib as Single Agent in Patients With 
mCRC With Any RAS or BRAF Mutation 
Previously Treated With FOLFOXIRI Plus 
Bevacizumab 
Second PFS at 6 
months 
 
 NCT01996969 Exploratory Identification of Predictive Biomarker of 
Regorafenib in Refractory Colorectal Cancer 
Third or 
beyond 
Biomarkers  
 NCT02175095 Exploratory  18F]FLT-PET as a Predictive Imaging 
Biomarker of Treatment Responses to 
Regorafenib 
Third or 
beyond 
Biomarkers 
 
FOLFOX=5-FU and oxaliplatin, Bev=Bevacizumab, mCRC=Metastatic colorectal 
cancer, CTCs=Circulating tumour cells, PFS=Progression free survival, OS=Overall 
survival, FOLFIRI=5-FU and irinotecan, DLT=Dose limiting toxicity, R2PD= 
Recommended phase II dose, DCE-US= Dynamic contrast enhanced ultrasound 
scan, FOLFOXIRI=5-FU, oxaliplatin and irinotecan, FLT-PET= Positron emission 
tomography (PET) tracer 3'-deoxy-3'[(18)F]-fluorothymidine, [(18)F]-FLT 
